Evidence map›Paper›PMID 34350523›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2022

Rapid molecular detection of pathogenic microorganisms and antimicrobial resistance markers in blood cultures: evaluation and utility of the next-generation FilmArray Blood Culture Identification 2 panel.

Tanja Holma, Jukka Torvikoski, Nathalie Friberg, Annika Nevalainen, Eveliina Tarkka, Jenni Antikainen, Jari J Martelin

Erratum issued Registry-linked trialAbstract read
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07684300 (Impact of Molecular Microbiology Integrated With Clinical Data on Antimicrobial Therapy Optimization), which is not on this map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07684300 narecruitingnot on this mapstarted 2026, after this paper: background citation

Impact of Molecular Microbiology Integrated With Clinical Data on Antimicrobial Therapy Optimization: An Open-Label Cluster-Randomized Crossover Trial

TypeinterventionalSponsorMaria Espinosa PerezRan2026 to 2027Enrolled250ConditionsInfection, Antimicrobial Stewardship Program, Antimicrobial Resistance, Multiplex PCRArmsProtocolized Antimicrobial Stewardship Strategy, Standard Antimicrobial Stewardship
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Diagnostic stewardship in sepsis: minding the gap from the microbiology lab to ward.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025
    Review
  10. Article
  11. [Efficiency and Usefulness of the Molecular Test 'BiofireAnnals of burns and fire disasters · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Evaluation of a new protocol for rapid identification ofJournal of clinical microbiology · 2025
    Article
  16. Article
  17. MAST® D72C test: a novel option for ESBL, AmpC and carbapenemase detection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
  18. Article
  19. The impact of the BIOFIREEuropean journal of pediatrics · 2024
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Tanja HolmaHUS Diagnostic Center, HUSLAB, Department of Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. tanja.holma@hus.fi.
Jukka TorvikoskiHUS Diagnostic Center, HUSLAB, Department of Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Nathalie FribergHUS Diagnostic Center, HUSLAB, Department of Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Annika NevalainenHUS Diagnostic Center, HUSLAB, Department of Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Eveliina TarkkaHUS Diagnostic Center, HUSLAB, Department of Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Jenni AntikainenHUS Diagnostic Center, HUSLAB, Department of Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
Jari J MartelinHUS Diagnostic Center, HUSLAB, Department of Clinical Microbiology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rapid detection of pathogens causing bloodstream infections (BSI) directly from positive blood cultures is of highest importance in order to enable an adequate and timely antimicrobial therapy. In this study, the utility and performance of a recently launched next-generation fully automated test system, the Biofire FilmArray® Blood Culture Identification 2 (BCID2) panel, was evaluated using a set of 103 well-characterized microbial isolates including 29 antimicrobial resistance genes and 80 signal-positive and 23 signal-negative clinical blood culture samples. The results were compared to culture-based reference methods, MALDI-TOF, and/or 16S rDNA sequencing. Of the clinical blood culture samples, 68 were monomicrobial (85.0%) and 12 polymicrobial (15.0%). Six samples contained ESBL (bla

Indexed as

Anti-Infective AgentsBacteremiaAnti-Bacterial AgentsBacteriaBlood CultureDrug Resistance, BacterialHumansAnti-Bacterial AgentsAnti-Infective AgentsAntimicrobial resistanceBacteremiaBlood cultureBSIMolecular detection methodsRapid diagnostics

Identifiers

PMID34350523
PMCPMC8831274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.